Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited

  title={Lithium and bipolar mood disorder: the inositol-depletion hypothesis revisited},
  author={Adrian J. Harwood},
  journal={Molecular Psychiatry},
  • A. Harwood
  • Published 2005
  • Biology
  • Molecular Psychiatry
Inositol, a simple six-carbon sugar, forms the basis of a number of important intracellular signaling molecules. Over the last 35 years, a series of biochemical and cell biological experiments have shown that lithium (Li+) reduces the cellular concentration of myo-inositol and as a consequence attenuates signaling within the cell. Based on these observations, inositol-depletion was proposed as a therapeutic mechanism in the treatment of bipolar mood disorder. Recent results have added… 

Cellular consequences of inositol depletion.

Findings indicate that inositol and inositl-containing molecules, including phosphoinositides andinositol phosphates, have signalling and regulatory roles in many cellular processes and may lead to perturbation of a wide range of cellular functions, at least some of which may be associated with bipolar disorder.

Free and Bound Therapeutic Lithium in Brain Signaling.

A larger "connected" picture of lithium's diverse effects based on its competition as a free monocation with native cations or as a phosphate-bound polyanionic complex modulating the host protein function is presented.

Lithium: Bipolar disorder and neurodegenerative diseases Possible cellular mechanisms of the therapeutic effects of lithium

  • F. Mármol
  • Psychology, Biology
    Progress in Neuro-Psychopharmacology and Biological Psychiatry
  • 2008

Lithium: the pharmacodynamic actions of the amazing ion

Support is provided for a role for the inhibition of glycogen synthase kinase 3 and inositol monophosphatase in the pharmacodynamic actions of lithium, and how inhibition of these enzymes by lithium can lead to downstream effects of clinical relevance, both for mood disorders and neurodegenerative diseases.

Lithium as a Neuroprotective Agent for Bipolar Disorder: An Overview

  • E. Ochoa
  • Biology, Psychology
    Cellular and molecular neurobiology
  • 2021
It is not known whether Li + —induced neuroprotection is related to the inhibition of its putative molecular targets in a BD episode: the enzymes inositol-monophosphatase, (IMPase), glycogen-synthase-kinase 3β (GSK3), and Protein kinase C (PKC).

Lithium salts — Simple but magic

This review presents the diversity of effects of lithium ions on the organism emphasizing their potential clinical applications with minimal undesirable side effects and presents a schematic “Lithiometer”, comparing the range of Li+ concentrations that might be used for the treatment of acute pathologies with possible toxic effects of Li+.

Exploration of Lithium Ion Binding to Magnesium Bound Adenosine Triphosphate and Its Implications for Bipolar Disorder

A mechanism of action for lithium is proposed based on the formation of Mg·Li-complexes at dehydrated magnesium-phosphate sites and perhaps a role for ATP·Mg as a physiological carrier for Li + .

Mechanisms of action of mood-stabilizing drugs

A major part of this thesis focused on the enzyme prolyl oligopeptidase (PO), which is thought to modulate the phosphatidylinositol pathway, as shown from studies in Dictyostelium discoideum and human astroglioma cells.

Response to lithium in bipolar disorder: clinical and genetic findings.

It is demonstrated that response to lithium has been connected with the genotype of BDNF gene and serum BDNF levels and it is shown that ELR have normal cognitive functions and serumBDNF levels, even after long-term duration of the illness.

Current understanding of bipolar disorder: Toward integration of biological basis and treatment strategies

  • Tadafumi Kato
  • Biology, Psychology
    Psychiatry and clinical neurosciences
  • 2019
Biological studies of bipolar disorder initially focused on the mechanism of action for antidepressants and antipsychotic drugs, and the roles of monoamines have been extensively studied, but involvement of intracellular calcium signaling has been supported by genetics and cellular studies.



The high affinity inositol transport system--implications for the pathophysiology and treatment of bipolar disorder.

It is concluded that downregulation of SMIT could represent a common mechanism of action of mood stabilizers: inhibition of myo-inositol uptake that proceeds via the sodium/myo- inositol cotransport (SMIT).

A common mechanism of action for three mood-stabilizing drugs

It is shown that all three lithium, carbamazepine and valproic acid drugs inhibit the collapse of sensory neuron growth cones and increase growth cone area, suggesting a molecular basis for both bipolar affective disorder and its treatment.

Chronic treatment with both lithium and sodium valproate may normalize phosphoinositol cycle activity in bipolar patients

The objective of the present study was to test the hypothesis that chronic treatment with either lithium or sodium valproate in patients with bipolar mood disorder leads to a normalization in the activity of the PI‐cycle.

Lithium and Valproate Decrease Inositol Mass and Increase Expression of the Yeast INO1 and INO2Genes for Inositol Biosynthesis*

This is the first demonstration of increased expression of genes in the inositol biosynthetic pathway by both lithium and valproate, which has far-reaching implications for predicting genetic determinants of responsiveness and resistance to these agents.

Search for a common mechanism of mood stabilizers.

Valproate decreases inositol biosynthesis

Effects of lithium on platelet membrane phosphoinositides in bipolar disorder patients: a pilot study

This longitudinal study suggests that therapeutic doses of lithium significantly decrease platelet membrane PIP2 levels in vivo in bipolar disorder subjects, which may be related to lithium’s mechanism of action inipolar disorder.

Bipolar disorder: leads from the molecular and cellular mechanisms of action of mood stabilisers

The results suggest that regulation of signalling pathways may play a major part in the long-term actions of mood stabilisers and may exert underappreciated neuroprotective effects.